Universal Beteiligungs und Servicegesellschaft mbH Has $3.63 Million Stock Position in Bio-Rad Laboratories, Inc. $BIO

Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 54.0% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 12,956 shares of the medical research company’s stock after buying an additional 4,541 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Bio-Rad Laboratories were worth $3,633,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Quent Capital LLC acquired a new stake in shares of Bio-Rad Laboratories in the 3rd quarter valued at approximately $25,000. Farther Finance Advisors LLC lifted its stake in Bio-Rad Laboratories by 52.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 104 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 36 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its position in Bio-Rad Laboratories by 3,633.3% in the second quarter. Caitong International Asset Management Co. Ltd now owns 112 shares of the medical research company’s stock valued at $27,000 after buying an additional 109 shares in the last quarter. Geneos Wealth Management Inc. boosted its position in Bio-Rad Laboratories by 115.2% in the second quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock valued at $34,000 after buying an additional 76 shares in the last quarter. Finally, CWM LLC grew its stake in shares of Bio-Rad Laboratories by 82.0% during the third quarter. CWM LLC now owns 202 shares of the medical research company’s stock worth $57,000 after buying an additional 91 shares during the last quarter. Institutional investors and hedge funds own 65.24% of the company’s stock.

Insiders Place Their Bets

In other news, EVP James Barry sold 700 shares of Bio-Rad Laboratories stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $306.18, for a total value of $214,326.00. Following the completion of the transaction, the executive vice president directly owned 510 shares of the company’s stock, valued at approximately $156,151.80. This trade represents a 57.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 17.83% of the company’s stock.

Bio-Rad Laboratories Trading Up 0.6%

Shares of BIO stock opened at $299.42 on Thursday. Bio-Rad Laboratories, Inc. has a 1-year low of $211.43 and a 1-year high of $368.65. The company has a current ratio of 5.44, a quick ratio of 3.94 and a debt-to-equity ratio of 0.18. The stock has a market cap of $8.08 billion, a price-to-earnings ratio of -12.32 and a beta of 1.18. The stock has a 50-day moving average of $311.96 and a 200-day moving average of $297.62.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Wednesday, October 29th. The medical research company reported $2.26 EPS for the quarter, missing the consensus estimate of $2.30 by ($0.04). The company had revenue of $653.00 million during the quarter, compared to the consensus estimate of $651.30 million. Bio-Rad Laboratories had a negative net margin of 26.43% and a positive return on equity of 4.19%. The business’s revenue was up .5% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.01 earnings per share. On average, equities research analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on BIO. Wall Street Zen upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research note on Monday, December 29th. Citigroup upped their price objective on Bio-Rad Laboratories from $350.00 to $375.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Finally, Wells Fargo & Company raised their price objective on shares of Bio-Rad Laboratories from $265.00 to $340.00 and gave the company an “equal weight” rating in a report on Thursday, October 30th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $358.50.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.